Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

r the three and nine months ended September 30, 2011 includes a $16.2 million in-process research and development asset impairment charge.Conference CallMylan will host a conference call and live audio webcast today, Wednesday, October 26, 2011, at 8:30 a.m. ET, in conjunction with the release of its financial results.  The dial-in number to access the call is 877.402.3913 or 817.382.5964 for international callers. A replay, available for approximately seven days, will be available at 800.585.8367 or 404.537.3406 for international callers with access pass code 12176566. To access a live audio webcast of the call, please log on to Mylan's website (www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on www.mylan.com for approximately seven days.

About MylanMylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

Forward Looking StatementsThis press release includes statements that constitute "forward-looking statements", including with regard to the company's future operations, its earnings expectations, its growth targets and anticipated product launches. These statements are made pursuant to the safe harbor provisions of the Pr
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Life Technologies Announces Third Quarter 2011 Results
3. Insmed to Host 2011 Third Quarter Earnings Conference Call
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
8. HeartWare Schedules Third Quarter Conference Call and Webcast
9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Inc. (OTC: MSEL) operating under its principal brand ... of visual communications and brand imaging solutions, was awarded " ... 9th Annual American Business Awards Ceremony, in recognition of its ... solid results, despite prevailing economic turbulence. The American ...
... 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: ... present data for its two first-in-class diabetes drugs, ... and its investigational diabetes drug candidates BYDUREON™ (exenatide ... at the 71st Scientific Sessions of the American ...
... 2011 Scientists Drs. Samuel and Elenore Bogoch of BioRadar ... in Replikin Counts of the EHEC lethal strains of E. ... of E. Coli have been studied in laboratories in Germany ... in the public databases. Replikins are subsequences of the genome ...
Cached Biology Technology:Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 2Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 3Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 4Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 5Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 2Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 3Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 4Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 5Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 6Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 7Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 8Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... news release is available in German . ... millions of sperms every day in order to reproduce? And ... are the topic of the latest issue of the research ... 2014). The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld ... it is not unusual for a female to copulate with ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... top technological universities have come together to form ... brings together these leading engineering-based universities in the ... address global societal issues is through the joint ... top class research in science and technology. ...
... Scientists have completed the first study of microbes that ... the Gulf of Mexico, where conditions may resemble those ... was partially funded by the National Science Foundation (NSF), ... vents spew mud, oil, brine and gases that support ...
... Outreach efforts by the Translational Genomics Research Institute (TGen) ... the second year, TGen will help organize a cancer ... The 2nd annual Fort Defiance Cancer Awareness and Advocacy ... 8:30 a.m.-5 p.m. July 18 at the Navajo Nation ...
Cached Biology News:Global alliance of leading technological universities to address global societal issues 2Better living through chemistry 2Better living through chemistry 3TGen helps promote cancer awareness for vast Navajo Nation 2TGen helps promote cancer awareness for vast Navajo Nation 3
...
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Acetyl CoA Carboxylase Antibody...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Biology Products: